MC1R variant alleles and malignant melanoma risk in Israel

Gilli Galore-Haskel, Esther Azizi, Hamida Mohamdi, Alon Scope, Valérie Chaudru, Yael Laitman, Frida Barak, Felix Pavlotsky, Florence Demenais, Eitan Friedman

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


To evaluate the contribution of MC1R variants to malignant melanoma risk in Israeli Jews, sequencing of the MC1R gene was performed in 132 melanoma patients and 184 ethnically matched controls. Overall, 22 MC1R variants were detected, two were novel (M73I and 496_497insG). Using age and sex-adjusted logistic regression, one specific variant, R151C, conferred significantly increased melanoma risk among Ashkenazim (OR = 2.6, 95% CI: 1.3-5.3; p = 0.05 after Bonferroni correction). A gene dosage effect was noted, with significantly increased melanoma risk being observed in subjects with at least two variants whether when all variants are pooled (OR = 4.8, 95% CI: 2.0-11.2; p = 0.002 after Bonferroni correction) or when red hair colour (RHC) variants and non-RHC variants are distinguished (OR = 7.6, 95% CI: 2.8-20.3; p = 0.0004 after Bonferroni correction). If further studies support these findings, the assessment of MC1R status may be useful in identifying Jewish Israeli individuals at high risk for melanoma.

Original languageEnglish
Pages (from-to)2015-2022
Number of pages8
JournalEuropean Journal of Cancer
Issue number11
StatePublished - 1 Jul 2009
Externally publishedYes


  • Ashkenazi Jews
  • MC1R
  • Malignant melanoma risk
  • Sequence variants

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'MC1R variant alleles and malignant melanoma risk in Israel'. Together they form a unique fingerprint.

Cite this